<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="35554">Cardiovascular drugs</z:chebi> are used in pregnancy to treat maternal and fetal conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Mothers may also require drug therapy postpartum </plain></SENT>
<SENT sid="2" pm="."><plain>Most <z:chebi fb="1" ids="35554">cardiovascular drugs</z:chebi> taken by pregnant women can cross the placenta and therefore expose the developing embryo and fetus to their pharmacologic and teratogenic effects </plain></SENT>
<SENT sid="3" pm="."><plain>These effects are influenced by the intrinsic pharmacokinetic properties of a given drug and by the complex physiologic changes occurring during pregnancy </plain></SENT>
<SENT sid="4" pm="."><plain>Many drugs are also transferred into human milk with potential adverse effects on the nursing infant </plain></SENT>
<SENT sid="5" pm="."><plain>This article summarizes some of the literature concerning the risks and benefits of using <z:chebi fb="1" ids="35554">cardiovascular drugs</z:chebi> during pregnancy </plain></SENT>
</text></document>